OPKO Health, CAMP4 Therapeutics Ink Oligonucleotide Platform With Focus On Drug-Resistant Epilepsy

OPKO Health Inc OPK has entered into an exclusive worldwide agreement with privately-held CAMP4 Therapeutics Corporation (CAMP4) to develop, manufacture, and commercialize therapeutics utilizing the AntagoNAT technology.
AntagoNATs are oligonucleotide compounds that target non-coding natural antisense transcripts leading to an upregulation of a desired functional protein.
CAMP4 has prioritized OPKO's lead AntagoNAT compound to progress into clinical trials for Dravet syndrome.
Under the terms of the agreement, OPKO will receive an upfront payment and shares of CAMP4.
In addition, OPKO will be eligible to receive up to $93.5 million and additional shares as milestone payments. CAMP4 will also pay OPKO double-digit royalties on product sales.
Price Action: OPK shares are down 2.25% at $3.92 during the market session on the last check Monday.